Why the study?
Current inducible RfxCas13d systems express CRISPR RNA and Cas13d separately, which can be cumbersome to handle and may hamper applications in certain scenarios.
The development of an all-in-one, doxycycline-inducible Cas13d lentivirus vector enables efficient and reversible RNA knockdown, particularly useful for studying indispensable genes or in hard-to-transduce cells.
May streamline inducible RfxCas13d use in mammalian cells; leaves open efficiency gains versus separate-expression systems.
Type VI CRISPR effector Cas13d from Ruminococcus flavefaciens XPD3002 (RfxCas13d) is an RNA-guided RNA endonuclease. RfxCas13d has been harnessed to knockdown gene expression with high specificity in various systems including mammalian cells. While inducible knockdown is advantageous over constitutive knockdown in many scenarios, current inducible systems of RfxCas13d express CRISPR RNA and Cas13d separately. Such systems could be cumbersome to handle and may hamper the application of RfxCas13d in some scenarios. Here, we design an all-in-one Cas13d lentivirus vector which renders efficient and inducible knockdown in a doxycycline dosage-dependent manner. Furthermore, we find that Cas13d has a short half-life in mammalian cells. As a result, knockdown can be promptly reversed after doxycycline withdrawal. This vector is particularly useful for applications involving indispensable genes and/or in cells hard to transduce.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: